Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul G Corn

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) SeriesNicolas Anselmino, Estefania Labanca, Peter D A Shepherd, et al.
European Urology Oncology|October 13, 2023
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary TractOmar Alhalabi, Nathaniel Wilson, Lianchun Xiao, et al.
JAMA Oncology|April 6, 2023
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical TrialChad Tang, Alexander D Sherry, Cara Haymaker, et al.
The Lancet. Oncology|February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaborationChad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
Science Signaling|May 25, 2017
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancerLikun Li, Styliani Karanika, Guang Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate CancerAna M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2026
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Solid Tumors: Primary Analysis of All Tumor-Histology Baskets of the Phase II Randomized EXTEND TrialAlexander D Sherry, Cara Haymaker, Shuqi Wang, et al.
Iscience|June 15, 2026
Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancersElavarasan Subramani, Patrick G Pilié, Rebecca Slack-Tidwell, et al.
European Urology|August 1, 2025
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND TrialAlexander D Sherry, Bilal A Siddiqui, Cara Haymaker, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) SeriesNicolas Anselmino, Estefania Labanca, Peter D A Shepherd, et al.
European Urology Oncology|October 13, 2023
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary TractOmar Alhalabi, Nathaniel Wilson, Lianchun Xiao, et al.
JAMA Oncology|April 6, 2023
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical TrialChad Tang, Alexander D Sherry, Cara Haymaker, et al.
The Lancet. Oncology|February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaborationChad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
Science Signaling|May 25, 2017
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancerLikun Li, Styliani Karanika, Guang Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate CancerAna M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2026
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Solid Tumors: Primary Analysis of All Tumor-Histology Baskets of the Phase II Randomized EXTEND TrialAlexander D Sherry, Cara Haymaker, Shuqi Wang, et al.
Iscience|June 15, 2026
Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancersElavarasan Subramani, Patrick G Pilié, Rebecca Slack-Tidwell, et al.
European Urology|August 1, 2025
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND TrialAlexander D Sherry, Bilal A Siddiqui, Cara Haymaker, et al.
Pageof 10